AAPL309.12-1.54 (-0.50%) ▼|ABBV253.27-1.37 (-0.54%) ▼|ABT95.01-0.81 (-0.85%) ▼|ACN140.12-1.99 (-1.40%) ▼|ADBE217.91-3.63 (-1.64%) ▼|AMAT575.47+20.97 (+3.78%) ▲|AMD519.80+3.69 (+0.72%) ▲|AMGN367.34-0.77 (-0.21%) ▼|AMT165.02-0.24 (-0.14%) ▼|AMZN242.13-3.85 (-1.57%) ▼|AVGO385.48+14.70 (+3.96%) ▲|AXP342.18-7.40 (-2.12%) ▼|BA227.95-3.74 (-1.61%) ▼|BAC59.17-0.70 (-1.16%) ▼|BKNG175.20-6.75 (-3.71%) ▼|BLK994.00-15.43 (-1.53%) ▼|BMY57.80-0.17 (-0.29%) ▼|BNY152.34-0.57 (-0.37%) ▼|BRK-B501.49-2.52 (-0.50%) ▼|C139.59-1.18 (-0.84%) ▼|CAT946.52+6.40 (+0.68%) ▲|CL92.87-2.17 (-2.28%) ▼|CMCSA23.55+0.14 (+0.58%) ▲|COF197.42-5.48 (-2.70%) ▼|COP109.87+1.43 (+1.32%) ▲|COST957.15+9.65 (+1.02%) ▲|CRM165.50-4.02 (-2.37%) ▼|CSCO112.38+0.59 (+0.53%) ▲|CVS105.25+0.92 (+0.88%) ▲|CVX175.93+1.92 (+1.10%) ▲|DE597.48-6.13 (-1.02%) ▼|DHR191.72-2.47 (-1.27%) ▼|DIS97.21-0.27 (-0.28%) ▼|DUK128.31+0.09 (+0.07%) ▲|EMR135.46-2.45 (-1.78%) ▼|FDX311.44-1.44 (-0.46%) ▼|GD374.00-0.64 (-0.17%) ▼|GE361.30-5.68 (-1.55%) ▼|GEV1,093.93+16.85 (+1.56%) ▲|GILD135.86-0.50 (-0.37%) ▼|GM76.20+0.17 (+0.22%) ▲|GOOG359.82-3.80 (-1.05%) ▼|GOOGL362.48-4.56 (-1.24%) ▼|GS1,032.02-10.96 (-1.05%) ▼|HD333.12-12.09 (-3.50%) ▼|HON220.32-4.74 (-2.10%) ▼|IBM299.75-6.38 (-2.08%) ▼|INTC109.07-1.33 (-1.20%) ▼|INTU272.35-8.83 (-3.14%) ▼|ISRG418.34-8.96 (-2.10%) ▼|JNJ266.94-0.30 (-0.11%) ▼|JPM334.36-4.87 (-1.43%) ▼|KO84.43+0.38 (+0.45%) ▲|LIN528.14-10.09 (-1.87%) ▼|LLY1,228.19-7.37 (-0.60%) ▼|LMT532.13-3.25 (-0.61%) ▼|LOW213.47-7.44 (-3.37%) ▼|LRCX334.12+7.99 (+2.45%) ▲|MA522.71-8.91 (-1.68%) ▼|MCD277.59-4.62 (-1.64%) ▼|MDLZ59.35-0.87 (-1.44%) ▼|MDT82.63-1.20 (-1.43%) ▼|META605.14-10.44 (-1.70%) ▼|MMM155.21-2.80 (-1.77%) ▼|MO73.45+0.49 (+0.67%) ▲|MRK126.62-2.24 (-1.74%) ▼|MS219.80-2.24 (-1.01%) ▼|MSFT383.58-5.26 (-1.35%) ▼|MU950.94+12.56 (+1.34%) ▲|NEE88.29-0.18 (-0.20%) ▼|NFLX75.10-1.09 (-1.42%) ▼|NKE42.48-0.73 (-1.69%) ▼|NOW105.86-4.87 (-4.40%) ▼|NVDA197.40+0.47 (+0.24%) ▲|ORCL140.70-0.91 (-0.64%) ▼|PEP143.99-0.99 (-0.68%) ▼|PFE24.17+0.10 (+0.42%) ▲|PG149.50-3.25 (-2.13%) ▼|PLTR128.06-6.32 (-4.70%) ▼|PM187.76-0.04 (-0.02%) ▼|QCOM184.73+1.76 (+0.96%) ▲|RTX199.72-1.13 (-0.56%) ▼|SBUX102.36-1.25 (-1.21%) ▼|SCHW102.74+0.81 (+0.79%) ▲|SO97.03-0.26 (-0.27%) ▼|SPG224.02-3.17 (-1.40%) ▼|T21.12+0.03 (+0.12%) ▲|TMO509.24-7.38 (-1.43%) ▼|TMUS181.11-3.63 (-1.96%) ▼|TSLA394.39-8.51 (-2.11%) ▼|TXN299.91+6.61 (+2.25%) ▲|UBER73.84-0.50 (-0.67%) ▼|UNH429.40+1.21 (+0.28%) ▲|UNP283.00-0.12 (-0.04%) ▼|UPS111.20-0.76 (-0.68%) ▼|USB61.80-1.09 (-1.73%) ▼|V346.83-5.37 (-1.52%) ▼|VZ42.96+0.37 (+0.88%) ▲|WFC86.35-0.83 (-0.95%) ▼|WMT112.84+1.30 (+1.17%) ▲|XOM141.14-0.55 (-0.39%) ▼|AAPL309.12-1.54 (-0.50%) ▼|ABBV253.27-1.37 (-0.54%) ▼|ABT95.01-0.81 (-0.85%) ▼|ACN140.12-1.99 (-1.40%) ▼|ADBE217.91-3.63 (-1.64%) ▼|AMAT575.47+20.97 (+3.78%) ▲|AMD519.80+3.69 (+0.72%) ▲|AMGN367.34-0.77 (-0.21%) ▼|AMT165.02-0.24 (-0.14%) ▼|AMZN242.13-3.85 (-1.57%) ▼|AVGO385.48+14.70 (+3.96%) ▲|AXP342.18-7.40 (-2.12%) ▼|BA227.95-3.74 (-1.61%) ▼|BAC59.17-0.70 (-1.16%) ▼|BKNG175.20-6.75 (-3.71%) ▼|BLK994.00-15.43 (-1.53%) ▼|BMY57.80-0.17 (-0.29%) ▼|BNY152.34-0.57 (-0.37%) ▼|BRK-B501.49-2.52 (-0.50%) ▼|C139.59-1.18 (-0.84%) ▼|CAT946.52+6.40 (+0.68%) ▲|CL92.87-2.17 (-2.28%) ▼|CMCSA23.55+0.14 (+0.58%) ▲|COF197.42-5.48 (-2.70%) ▼|COP109.87+1.43 (+1.32%) ▲|COST957.15+9.65 (+1.02%) ▲|CRM165.50-4.02 (-2.37%) ▼|CSCO112.38+0.59 (+0.53%) ▲|CVS105.25+0.92 (+0.88%) ▲|CVX175.93+1.92 (+1.10%) ▲|DE597.48-6.13 (-1.02%) ▼|DHR191.72-2.47 (-1.27%) ▼|DIS97.21-0.27 (-0.28%) ▼|DUK128.31+0.09 (+0.07%) ▲|EMR135.46-2.45 (-1.78%) ▼|FDX311.44-1.44 (-0.46%) ▼|GD374.00-0.64 (-0.17%) ▼|GE361.30-5.68 (-1.55%) ▼|GEV1,093.93+16.85 (+1.56%) ▲|GILD135.86-0.50 (-0.37%) ▼|GM76.20+0.17 (+0.22%) ▲|GOOG359.82-3.80 (-1.05%) ▼|GOOGL362.48-4.56 (-1.24%) ▼|GS1,032.02-10.96 (-1.05%) ▼|HD333.12-12.09 (-3.50%) ▼|HON220.32-4.74 (-2.10%) ▼|IBM299.75-6.38 (-2.08%) ▼|INTC109.07-1.33 (-1.20%) ▼|INTU272.35-8.83 (-3.14%) ▼|ISRG418.34-8.96 (-2.10%) ▼|JNJ266.94-0.30 (-0.11%) ▼|JPM334.36-4.87 (-1.43%) ▼|KO84.43+0.38 (+0.45%) ▲|LIN528.14-10.09 (-1.87%) ▼|LLY1,228.19-7.37 (-0.60%) ▼|LMT532.13-3.25 (-0.61%) ▼|LOW213.47-7.44 (-3.37%) ▼|LRCX334.12+7.99 (+2.45%) ▲|MA522.71-8.91 (-1.68%) ▼|MCD277.59-4.62 (-1.64%) ▼|MDLZ59.35-0.87 (-1.44%) ▼|MDT82.63-1.20 (-1.43%) ▼|META605.14-10.44 (-1.70%) ▼|MMM155.21-2.80 (-1.77%) ▼|MO73.45+0.49 (+0.67%) ▲|MRK126.62-2.24 (-1.74%) ▼|MS219.80-2.24 (-1.01%) ▼|MSFT383.58-5.26 (-1.35%) ▼|MU950.94+12.56 (+1.34%) ▲|NEE88.29-0.18 (-0.20%) ▼|NFLX75.10-1.09 (-1.42%) ▼|NKE42.48-0.73 (-1.69%) ▼|NOW105.86-4.87 (-4.40%) ▼|NVDA197.40+0.47 (+0.24%) ▲|ORCL140.70-0.91 (-0.64%) ▼|PEP143.99-0.99 (-0.68%) ▼|PFE24.17+0.10 (+0.42%) ▲|PG149.50-3.25 (-2.13%) ▼|PLTR128.06-6.32 (-4.70%) ▼|PM187.76-0.04 (-0.02%) ▼|QCOM184.73+1.76 (+0.96%) ▲|RTX199.72-1.13 (-0.56%) ▼|SBUX102.36-1.25 (-1.21%) ▼|SCHW102.74+0.81 (+0.79%) ▲|SO97.03-0.26 (-0.27%) ▼|SPG224.02-3.17 (-1.40%) ▼|T21.12+0.03 (+0.12%) ▲|TMO509.24-7.38 (-1.43%) ▼|TMUS181.11-3.63 (-1.96%) ▼|TSLA394.39-8.51 (-2.11%) ▼|TXN299.91+6.61 (+2.25%) ▲|UBER73.84-0.50 (-0.67%) ▼|UNH429.40+1.21 (+0.28%) ▲|UNP283.00-0.12 (-0.04%) ▼|UPS111.20-0.76 (-0.68%) ▼|USB61.80-1.09 (-1.73%) ▼|V346.83-5.37 (-1.52%) ▼|VZ42.96+0.37 (+0.88%) ▲|WFC86.35-0.83 (-0.95%) ▼|WMT112.84+1.30 (+1.17%) ▲|XOM141.14-0.55 (-0.39%) ▼|
25 C
New York
Wednesday, July 8, 2026

Tag: plans

newssourceFORcompanyinformationcontent1releasesmarket

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients

Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis...

Ahead of the $3 XRP Era, PFMCrypto Launches 2-Day XRP Mining Promotion, $1 Million Giveaway Sparks Community Excitement

As XRP appears poised to surge to $3 in June, leading XRP mining platform PFMCrypto has launched a 48-hour exclusive XRP mining promotion, giving away $1 million USD in rewards to its global user base 
As XRP appears poised to surge to $3 in June, leading XRP mining platform PFMCrypto has launched a 48-hour exclusive XRP mining promotion, giving away $1 million USD in rewards to its global user base

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

Cheap AI Bots Eye Junior Coders’ Lunch

In 2007, Luke Arrigoni pulled in $63,000 as a junior software developer. Fast forward to today, and AI tools that supposedly churn out better...

Gold Coast Health Plan Denounces Sharing of Medicaid Enrollment Data with Department of Homeland Security

CAMARILLO, Calif., June 14, 2025 /PRNewswire/ -- Gold Coast Health Plan (GCHP), the local Medi-Cal plan for Ventura County, is deeply concerned about the...

A.I. Saves Ad Industry—Until It Doesn’t.

The Cannes Lions Festival of Creativity, a glorified playground for ad executives who enjoy sipping overpriced cocktails while convincing themselves they're the maestros of...

SL Benfica President Rui Costa Inaugurates Portuguese club’s new Residential Academy in Florida

The "Eagles" have taken their world-famous player development methodology to the United States TAMPA, Fla., June 14, 2025 /PRNewswire/ -- SL Benfica President Rui Costa...

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPlans

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers